Aktienanalyse zu Nasus Pharma Ltd (NSRX)NSRXNasus Pharma Ltd

Nasus Pharma Ltd. is an Israel-based pharmaceutical company. The Company develops and manufactures pharmaceutical products and intranasal powder-based drug delivery systems. Its proprietary microsphere technology is designed to enable non-invasive intranasal administration of medications for emergency and acute-care applications, including the treatment of anaphylaxis and opioid overdose. The Company's formulations are designed to support rapid drug absorption and administration without the use of injections. Nasus Pharma Ltd. focuses on the development of drug delivery solutions intended for use by healthcare professionals, caregivers, first responders, and other non-professional users. The Company's products aim to improve the accessibility and administration of critical medications in emergency situations. It operates in the Healthcare sector.

Nasus Pharma Ltd is a good buy right now due to its recent FDA clearance for NS002, which positions the company for potential growth in the allergy medication market. The current price is $3.20, significantly below the analyst price target of $7, indicating a potential upside of 118.75%. Additionally, the RSI is at 44.39, suggesting that the stock is not overbought, and there is room for upward momentum. However, the company has a high net loss of $5.9 million for 2025 and a current ratio of 8.77, indicating liquidity but also the need for careful monitoring of cash flow.